Bacillus Calmette-Guérin immunotherapy for refractory interstitial cystitis

Area of Science:

• Urology
• Immunotherapy
• Inflammatory Conditions

Background:

• Interstitial cystitis (IC) is a chronic bladder condition causing pain and urinary urgency.
• Refractory IC cases often fail to respond to conservative treatments.
• Intravesical bacillus Calmette-Guérin (BCG) is an immunotherapy typically used for bladder cancer.

Purpose of the Study:

• To evaluate the efficacy of intravesical BCG immunotherapy in patients with refractory interstitial cystitis.
• To assess the impact of BCG on symptom severity and bladder function in IC patients.

Main Methods:

• A cohort of five patients with refractory IC received six weekly intravesical BCG instillations.
• Patients were assessed pre-treatment and quarterly post-treatment using water cystometry and symptom questionnaires.
• Key outcome measures included medication usage, bladder capacity, urinary frequency, nocturia, and pain levels.

Main Results:

• Significant improvements were observed in cystometric capacity (P = 0.0277), daytime urinary frequency (P = 0.0131), nocturia (P = 0.0199), and global pain (P = 0.0317).
• The average daily medication use decreased from 3.2 to 1.2 per patient.
• Three out of five patients experienced substantial symptom relief within 6-12 months of follow-up.

Conclusions:

• Intravesical BCG immunotherapy may offer a beneficial treatment option for patients with refractory interstitial cystitis.
• The precise mechanism of BCG's action in IC requires further investigation.
• A double-blind, placebo-controlled trial is recommended to validate these findings and establish optimal treatment protocols.